Health  Vol.5 No.5 A , May 2013
ATP binding cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia

Purpose: In acute lymphoblastic leukemia (ALL), multidrug resistance is often mediated by AT- Pase Binding Cassette (ABC) proteins, which principally involve ABCC1 (multidrug resistance protein 1, MRP1) and ABCB1 (multidrug resistance 1, MDR1). However, direct comparisons between the differential effects of ABCC1 and ABCB1 have been difficult, since identical cell lines with differential expression of these transporters have not been developed. Experimental Design: In this study, we developed and compared the biological profiles of Jurkat cell lines that selectively over-expressed ABCC1 and ABCB1. Vincristine (VCR) plays an important role in the treatment of T-lineage ALL (T-ALL), and is often the first drug given to newly-diagnosed patients. Because of its importance in treatment, we provide descalating, sub-lethal doses of VCR to Jurkat cells, and extended our observations to expression profiling of newly diagnosed patients with T-ALL. Results: We found that VCR-resistant cells over-expressed ABCC1 nearly 30-fold. The calcein AM assay confirmed that VCR-resistant cells actively extruded VCR, and that ABCC1-mediated drug resistance conferred a different spectrum of multidrug resistance than other T-ALL induction agents. siRNA experiments that blocked ABCC1 export confirmed that VCR resistance could be reversed in vitro. Analyses of T-lymphoblasts obtained from 100 newly diagnosed T-ALL patients treated on Children’s Oncology Group Phase III studies 9404 and AALL0434 that induction failure could be could be partially explained by the over-expression of ABCC1 and ABCB1. Conclusions: Taken together, these results suggest that over-expression of ABC transporters plays a contributing role in mediating treatment failure in T-ALL, and underscore the need to employ alternate treatment approaches in patients for whom induction failed or for those with relapsed disease.

Cite this paper: Winter, S. , Ricci, J. , Luo, L. , Lovato, D. , Khawaja, H. , Serna-Gallegos, T. , DeBassige, N. and Larson, R. (2013) ATP binding cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia. Health, 5, 41-50. doi: 10.4236/health.2013.55A005.

[1]   Trigg, M.E., Sather, H.N., Reaman, G.H., et al. (2008) Ten- year survival of children with acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Leuk Lymphoma, 49, 1142-1154. doi:10.1080/10428190802074593

[2]   Vrooman, L.M. and Silverman, L.B. (2009) Childhood acute lymphoblastic leukemia: Update on prognostic factors. Current Opinion in Pediatrics, 21, 1-8. doi:10.1097/MOP.0b013e32831f1f24

[3]   Chang, G. (2003) Multidrug resistance ABC transporters. FEBS Letters, 555, 102-105. doi:10.1016/S0014-5793(03)01085-8

[4]   Altenberg, G.A. (2004) Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Current Medicine Chemistry and Anti-Cancer Agents, 4, 53-62. doi:10.2174/1568011043482160

[5]   Szakacs, G., Annereau, J.P., Lababidi, S., et al. (2004) Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell, 6, 129-137. doi:10.1016/j.ccr.2004.06.026

[6]   Steinbach, D., Wittig, S., Cario, G., et al. (2003) The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood, 102, 4493-4498. doi:10.1182/blood-2002-11-3461

[7]   Efferth, T., Gillet, J.P., Sauerbrey, A., et al. (2006) Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Molecular Cancer Therapy, 5, 1986-1994. doi:10.1158/1535-7163.MCT-06-0086

[8]   Estes, D.A., Lovato, D.M., Khawaja, H.M., et al. (2007) Genetic alterations determine chemotherapy resistance in childhood T-ALL: Modelling in stage-specific cell lines and correlation with diagnostic patient samples. British Journal of Haematology, 139, 20-30. doi:10.1111/j.1365-2141.2007.06763.x

[9]   Leonard, G.D., Fojo, T. and Bates, S.E. (2003) The role of ABC transporters in clinical practice. Oncologist, 8, 411424. doi:10.1634/theoncologist.8-5-411

[10]   Plasschaert, S.L., Vellenga, E., de Bont, E.S., et al. (2003) High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma, 44, 85-95. doi:10.1080/1042819021000040288

[11]   Wuchter, C., Karawajew, L., Ruppert, V., et al. (2000) Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 110, 154-160. doi:10.1046/j.1365-2141.2000.02147.x

[12]   van Grotel, M., van den Heuvel-Eibrink, M.M., van Wering, E.R., et al. (2008) CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. Pediatric Blood Cancer, 51, 737-740. doi:10.1002/pbc.21707

[13]   Amylon, M.D., Shuster, J., Pullen, J., et al. (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia, 13, 335-342. doi:10.1038/sj.leu.2401310

[14]   Goldberg, J.M., Silverman, L.B., Levy, D.E., et al. (2003) Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. Journal of Clinical Oncology, 21, 3616-3622. doi:10.1200/JCO.2003.10.116

[15]   Gutierrez, A., Dahlberg, S.E., Neuberg, D.S., et al. (2010) Absence of biallelic TCR gamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. Journal of Clinical Oncology, 28, 3816-3823. doi:10.1200/JCO.2010.28.3390

[16]   Winter, S.S., Holdsworth, M.T., Devidas, M., et al. (2006) Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: A report of POG study 9296. Pediatric Blood Cancer, 46, 179-186. doi:10.1002/pbc.20429

[17]   Winter, S.S., Jiang, Z., Khawaja, H.M., et al. (2007) Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Blood, 110, 1429-1438. doi:10.1182/blood-2006-12-059790

[18]   Ivnitski-Steele, I., Holmes, A.R., Lamping, E., et al. (2009) Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Analytical Biochemistry, 394, 87-91. doi:10.1016/j.ab.2009.07.001

[19]   Edwards, B.S., Bologa, C., Young, S.M., et al. (2005) Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Molecular Pharmacology, 68, 1301-1310. doi:10.1124/mol.105.014068

[20]   Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402- 408. doi:10.1006/meth.2001.1262

[21]   Holleman, A., Cheok, M.H., den Boer, M.L., et al. (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. New England Journal of Medicine, 351, 533-542. doi:10.1056/NEJMoa033513

[22]   Perrotton, T., Trompier, D., Chang, X.B., et al. (2007) (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. Journal of Biological Chemistry, 282, 31542- 31548. doi:10.1074/jbc.M703964200

[23]   Den Boer, M.L., Kapaun, P., Pieters, R., et al. (1999) Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: Relationship with in vitro drug resistance. British Journal of Haematology, 105, 876-882. doi:10.1046/j.1365-2141.1999.01440.x

[24]   Efferth, T., Sauerbrey, A., Steinbach, D., et al. (2003) Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. International Journal of Oncology, 23, 509-517.

[25]   Breit, S., Stanulla, M., Flohr, T., et al. (2006) Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood, 108, 1151-1157. doi:10.1182/blood-2005-12-4956

[26]   Schroeder, H., Garwicz, S., Kristinsson, J., et al. (1995) Outcome after first relapse in children with acute lymphoblastic leukemia: A population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Medicine Pediatric Oncology, 25, 372-378. doi:10.1002/mpo.2950250503

[27]   Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A children’s oncology group study. Journal of Clinical Oncology, 26, 3971-3978. doi:10.1200/JCO.2008.16.1414

[28]   Gutierrez, A., Sanda, T., Grebliunaite, R., et al. (2009) High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood, 114, 647650. doi:10.1182/blood-2009-02-206722

[29]   Kobayashi, H., Takemura, Y., Holland, J.F., et al. (1998) Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: Mechanism of inoculum effect. Biochemical Pharmacology, 55, 1229-1234. doi:10.1016/S0006-2952(97)00615-1

[30]   McCune, J.S. and Lindley, C. (1997) Appropriateness of maximum-dose guidelines for vincristine. American Journal of Health-System Pharmacy, 54, 1755-1758.

[31]   Szakacs, G., Varadi, A., Ozvegy-Laczka, C., et al. (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discovery Today, 13, 379-393. doi:10.1016/j.drudis.2007.12.010

[32]   Fotoohi, A.K., Assaraf, Y.G., Moshfegh, A., et al. (2009) Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochemical Pharmacology, 77, 1410-1417. doi:10.1016/j.bcp.2008.12.026

[33]   Munoz, M., Henderson, M., Haber, M., et al. (2007) Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life, 59, 752-757. doi:10.1080/15216540701736285

[34]   Wuchter, C., Karawajew, L., Ruppert, V., et al. (1999) Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia, 13, 1943-1953. doi:10.1038/sj.leu.2401605

[35]   Coustan-Smith, E., Mullighan, C.G., Onciu, M., et al. (2009) Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncology, 10, 147-156. doi:10.1016/S1470-2045(08)70314-0

[36]   Homminga, I., Pieters, R., Langerak, A.W., et al. (2011) Integrated Transcript and Genome Analyses Reveal NKX2- 1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia. Cancer Cell, 19, 484-497. doi:10.1016/j.ccr.2011.02.008

[37]   Zhang, J., Ding, L., Holmfeldt, L., et al. (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 481, 157-163. doi:10.1038/nature10725

[38]   Donnenberg, V.S. and Donnenberg, A.D. (2005) Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. Journal of Clinical Oncology, 45, 872-877. doi:10.1177/0091270005276905

[39]   Donnenberg, V.S., Landreneau, R.J. and Donnenberg, A.D. (2007) Tumorigenic stem and progenitor cells: Implications for the therapeutic index of anti-cancer agents. Journal of Control Release, 122, 385-391. doi:10.1016/j.jconrel.2007.05.005

[40]   Berg, S.L., Blaney, S.M., Devidas, M., et al. (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children’s Oncology Group. Journal of Clinical Oncology, 23, 3376-3382. doi:10.1200/JCO.2005.03.426

[41]   Bermudez, M., Fuster, J.L., Llinares, E., et al. (2005) Itraconazole-related increased vincristine neurotoxicity: Case report and review of literature. Journal of Pediatric Hematology/Oncology, 27, 389-392. doi:10.1097/01.mph.0000172751.06286.5b